AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G/A] ABBVIE INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Schedule 13G Overview � The Vanguard Group & Ralliant Corp (RAL)

On 30 June 2025, The Vanguard Group filed a Schedule 13G reporting passive beneficial ownership of Ralliant Corp’s common stock. Vanguard now controls 13,174,096 shares, representing 11.65 % of RAL’s outstanding shares. The filing is made under Rule 13d-1(b) because Vanguard is an SEC-registered investment adviser ("IA").

Voting vs. dispositive authority

  • Sole voting power: 0 shares
  • Shared voting power: 49,118 shares
  • Sole dispositive power: 12,898,650 shares
  • Shared dispositive power: 275,446 shares

While Vanguard has virtually no direct voting power, it retains the right to dispose of nearly all of the reported shares, indicating the holding is spread across indexed and managed funds that delegate voting to third parties or follow fund-level policies.

Implications for investors

  • Crossing the 10 % threshold makes Vanguard a significant institutional holder, potentially increasing RAL’s visibility among passive and ETF-tracking investors.
  • The passive 13G filing (rather than an activist 13D) signals no intention to influence control or strategy.
  • Concentrated ownership may add liquidity support but could create share-supply risk if Vanguard trims its position.

The certification confirms the stake was acquired in the ordinary course of business and not to influence management. The document is signed by Ashley Grim, Head of Global Fund Administration, on 7 July 2025.

Positive
  • Large institutional endorsement: Vanguard’s 11.65 % stake signals confidence and may attract additional passive inflows.
  • Enhanced liquidity: A sizable index-fund position typically narrows bid-ask spreads and supports daily trading volume.
Negative
  • Concentration risk: Vanguard’s ability to dispose of nearly 13 million shares could pressure the stock if large redemptions occur.
  • Limited governance influence: Near-zero sole voting power means Vanguard is unlikely to advocate for shareholder-friendly changes.

Insights

TL;DR: Vanguard’s 11.65 % passive stake boosts liquidity and visibility but has limited governance impact.

Vanguard’s filing is routine for an index manager whose AUM pushes it above the 10 % threshold. The near-zero sole voting power shows most shares sit in funds that outsource proxy decisions or vote proportionally, so management should not expect activism. For investors, the presence of a mega-cap manager provides liquidity and may reduce volatility, yet the potential for large-block sales remains a technical overhang. Fundamentally, the filing does not alter RAL’s earnings outlook or strategy, so I consider the market impact modest and largely sentiment-based.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:07/07/2025

FAQ

How much of Ralliant Corp (RAL) does Vanguard now own?

Vanguard beneficially owns 13,174,096 shares, equating to 11.65 % of the outstanding common stock.

Is Vanguard’s filing activist or passive?

It is a passive Schedule 13G, indicating no intent to influence control or strategy.

What voting power does Vanguard hold in RAL?

Vanguard has 0 shares with sole voting power and 49,118 shares with shared voting power.

Why did Vanguard file on 30 June 2025?

Crossing the 10 % ownership threshold triggered a filing requirement on that event date.

Who signed the Schedule 13G for Vanguard?

The document was signed by Ashley Grim, Head of Global Fund Administration, on 7 July 2025.

Does Vanguard intend to influence Ralliant’s management?

No. The certification states the shares were acquired in the ordinary course of business without intent to influence control.
Abbvie Inc

NYSE:ABBV

ABBV Rankings

ABBV Latest News

ABBV Latest SEC Filings

ABBV Stock Data

334.34B
1.76B
0.12%
74.08%
1.05%
Drug Manufacturers - General
Pharmaceutical Preparations
United States
NORTH CHICAGO